Synermore Biologics (Suzhou) Co., Ltd.
π¨π³China
- Country
- π¨π³China
- Ownership
- Subsidiary
- Established
- 2016-08-10
- Employees
- -
- Market Cap
- -
- Website
- http://synermore.com
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
Phase 3
Completed
- Conditions
- Rhabdoviridae InfectionsRNA Virus InfectionsRabiesCommunicable DiseaseVirus DiseasesMononegavirales Infections
- Interventions
- Biological: Human Rabies Immune Globulin (HRIG)Biological: SYN023Biological: Rabies Vaccine
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT04644484
- Locations
- π¨π³
Yunnan Province Center for Disease Control and Prevention (CDC), Kunming, China
A Bridging Study of the SYN023 on Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Rabies HumanVaccine ReactionCommunicable Disease TransmissionImmunisation ReactionZoonotic Disease
- Interventions
- Biological: recombinant anti-rabies human monoclonal antibody injection (SYN023)Biological: Rabies Vaccine
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT04495569
- Locations
- π¨π³
Jilin University, Changchun City, Jilin, China
Β© Copyright 2025. All Rights Reserved by MedPath